Michael Pourdehnad, Senior Vice President, Head of Early Clinical Development, Hematology/Oncology & Cell Therapy at Bristol Myers Squibb, shared a post on LinkedIn:
“Proud to sit in the audience and watch the Phase 3 results from the SUCCESSOR-2 study presented at ASCO this year.
A very special congratulations to all the discovery, translational and early development colleagues that worked on this program with me. Its a remarkable work of translational medicine from the clinic to the lab bench and back to the clinic again. And very grateful to work with our late development teams who have brought this now to such an important stage in development.
Moments like this reflect years of dedication-from patients and investigators to the many teams across research, development, medical and operations who make this work possible.
Grateful to be part of a community pushing the science forward for patients – together.”
Other articles about ASCO on OncoDaily.